Text Size
202 studies found for:    Expanded Access Studies

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Approved for marketing Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
2 Available PFO ACCESS Registry
Conditions: Patent Foramen Ovale;   Stroke
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
3 Temporarily not available Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
4 Available Uridine Triacetate as an Antidote for Patients at Excess Risk of 5-Fluorouracil (5-FU) Toxicity Due to Overdosage or Impaired Elimination
Conditions: Toxicity Due to Chemotherapy;   Impaired 5FU Elimination
Intervention: Drug: uridine triacetate
5 No longer available Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Biological: Iodine I 131 Tositumomab Therapeutic Regimen
6 No longer available This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma
Intervention: Drug: Plerixafor
7 Available BMN 110 US Expanded Access Program
Conditions: Mucopolysaccharidosis IVA;   Morquio A Syndrome;   MPS IVA
Intervention: Drug: BMN 110
8 No longer available Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Condition: West Nile Virus Infection
Intervention: Biological: MGAWN1
9 Available Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders
Intervention: Drug: triheptanoin
10 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
Condition: HIV Infections
Intervention: Drug: Tipranavir
11 No longer available Stiripentol in Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: stiripentol
12 Approved for marketing Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Conditions: Cystic Fibrosis;   Pseudomonas Aeruginosa
Intervention: Drug: Aztreonam lysine
13 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
14 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
15 Unknown † Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib/Dexamethasone/Melphalan
16 Approved for marketing Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Drug: cabozantinib
17 Available Bivalirudin foR Acute Myocardial Infarction underGoing Angioplasty in CHinese patienTs.
Condition: Acute Myocardial Infarction
Intervention: Drug: Bivalirudin
18 No longer available Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program
Conditions: Hepatitis B;   Chronic Disease
Intervention: Drug: Entecavir
19 Approved for marketing Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization
Condition: Autologous Stem Cell Transplant
Intervention: Drug: AMD3100 + G-CSF
20 No longer available Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment
Condition: Valuable Suggestions to Improve Health Care Quality Transparent and Accessible Medical Care
Intervention: Behavioral: questionnaire
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years